Aptar Enters into Agreement with Weihai Hengyu Medical Products
Transaction Overview
Aptar
• Purchase Price: Under the contemplated transaction, and subject to the conditions
described in the press release, Aptar would acquire 80% ownership interest
Value: Enterprise valuation on a 100% cash and debt free basis of approximately
$77 million
• Option: Under the terms of the deal, Aptar has the option to acquire the remaining
20% after a 5-year lock up period
• Financial Impact: The transaction is not expected to have a material impact on
adjusted earnings per share in 2021 or 20221
• Financing: Funded with cash on hand
1Adjusted earnings per share is a non-GAAP financial measure. Additional information regarding this measure is available on the Company's website at www.aptar.com on the
Investor's page (click on Events & Presentations for a Reconciliation of non-GAAP Financial Measures).
5View entire presentation